No Detail Found!

EFFICACY AND COST EFFECTIVENESS OF BIOSIMILAR PEGYLATED INTERFERON α2a 180 µg/RIBAVIRIN IN NON-CIRRHOTIC TREATMENT NAÏVE GENOTYPE 3 PATIENTS

Author(s)
Asad A Chaudhry Gujranwala Liver Foundation, Gujranwala, Pakistan
Arif A Nawaz Gujranwala Liver Foundation, Gujranwala, Pakistan
Abdul Kafi Gujranwala Liver Foundation, Gujranwala, Pakistan
Muhammad Irfan Fatima Memorial Hospital, Lahore, Pakistan
Afsheen Jalal Gujranwala Liver Foundation, Gujranwala, Pakistan
Neeta Maheshwary Hilton Pharma, Karachi, Pakistan
Shaz Effendi Hilton Pharma, Karachi, Pakistan
Ahson Siddiqi Hilton Pharma, Karachi, Pakistan
Abstract
Background: Due to poor socio-economic status majority of the patients cannot afford the cost of investigations and treatment of chronic active hepatitis C which has compelled the local physicians to find cost effective ways of managing chronically infected hepatitis C patients. The objective of this study was to evaluate the efficacy and cost-effectiveness of biosimilar pegylated interferon a2a 180 µg and weight-based ribavirin, compared to pegylated interferon and ribavirin in treatment naïve GT3 patients. Methods: A total of 45 patients were recruited for the study out of which 39 patients completed the study protocol at Hepatology Clinic of Gujranwala Liver Foundation, Siddique Sadiq Hospital, Sheikhupura Road, Gujranwala, from Nov 2012 to Apr 2014. Patients with history of previous interferon-based therapy, liver cirrhosis, non GT3, hepatitis B co-infection, and organ transplant recipients were excluded. All patients were treated with biosimilar pegylated interferon a2a 180 µg and weight-based ribavirin in a response guided manner. Results: Out of the 39 patients who completed the study as per protocol, 92.3% achieved sustained virological SVR. Relapse rate was 13.1% and non-responders were 6%. Conclusion: Biosimilar pegylated interferon a2a 180 µg/ Ribavirin had a high SVR rate in carefully selected treatment naïve GT 3 non-cirrhotic patients. The results are comparable to Direct Acting Antiviral agent (DAA) which has higher cost.
Publication Details
Page(s) 26-28
DOI DOI not available
Published Journal: Pakistan Journal of Physiology, Volume: 12, Issue: 1, Year: 2016

Request the full text from PASTIC

Keywords
Efficacy, Hepatitis C, ribavirin, Antiviral therapy, Cost-effectiveness, Biosimilar pegylated interferon, Pegylated interferon
0

Citations

0

Downloads

81

Views